Goldman Sachs has revised its price target for Johnson & Johnson (JNJ), a constituent of the Dow Jones Industrial Average, reflecting updated valuation assumptions. The move follows broader reassessment of consumer staples sector dynamics and dividend sustainability in a shifting macroeconomic environment.
- Goldman Sachs lowered its price target for Johnson & Johnson (JNJ) to $170 from $185
- JNJ’s current dividend yield stands at 3.1%, supporting its appeal in income portfolios
- The stock closed on March 3, 2026, at approximately $165.10, implying a 3% upside at the new target
- JNJ remains a Dow Jones Industrial Average (DJI) constituent and S&P 500 top 30 stock
- The firm maintains a 'neutral' rating, citing litigation and pharmaceutical growth challenges
- Procter & Gamble (PG) and other Dow 30 dividend stocks may face similar valuation reevaluations
Goldman Sachs has lowered its price target for Johnson & Johnson (JNJ) to $170 per share, down from the previous $185, citing a reassessment of long-term growth prospects and litigation-related headwinds. The adjustment comes as the firm recalibrates its outlook for the consumer staples sector within the Dow Jones Industrial Average (^DJI), where JNJ remains a key dividend heavyweight. The new target implies a moderate upside of approximately 3% from JNJ’s closing price on March 3, 2026, reflecting a more cautious stance on earnings growth over the next 12 to 18 months. The firm maintains a 'neutral' rating on the stock, emphasizing that while JNJ’s dividend yield of 3.1% continues to support investor appeal, structural challenges in its pharmaceutical division and ongoing legal settlements are constraining near-term momentum. Johnson & Johnson, which also ranks among the top 30 companies in the S&P 500, continues to serve as a core holding for income-focused portfolios. With a market capitalization exceeding $420 billion and a history of consecutive annual dividend increases, JNJ remains a cornerstone in U.S. equity markets. The stock's performance is closely watched by institutional investors evaluating sector rotation strategies, particularly within the consumer staples and healthcare segments. Market impact was limited, with JNJ shares showing a 0.2% decline post-announcement. However, the action underscores the increasing scrutiny on large-cap dividend issuers amid elevated interest rates and persistent inflation. Competitors such as Procter & Gamble (PG), also a Dow 30 component, may face similar valuation reviews as analysts reassess sustainability of high yields in the current rate environment.